Renal coloboma syndrome (RCS, MIM#120330), also known as papillorenal syndrome, is an inherited autosomal dominant disease characterized by ocular and/or renal involvement due to PAX2 mutation. The renal involvement typically consists of a hypo/dysplatic kidney and/or vesicoureteral reflux. Recent studies reported that missense PAX2 mutations cause familial focal segmental glomerular sclerosis (FSGS) without renal morphological malformations. To date, the reports of genotypephenotype correlation including pathological findings regarding PAX2 mutations are scarce. We report a case of RCS with a novel PAX2 mutation that was pathologically diagnosed as FSGS and rapidly progressed to end-stage kidney failure (ESKD) with a review of past literature. A 6-year-old boy, who had bilateral coloboma and loss of vision in the left eye, was noted non-nephrotic proteinuria and renal dysfunction via school urine screening. Abdominal ultrasound showed no renal and urinary tract malformations and kidney biopsy showed FSGS. Genetic analysis revealed a novel insertion-deletion mutation in PAX2 (NM003987.4: c.70_72delinsA; p.Gly24Argfs*29). His kidney function deteriorated gradually during the following 2 years and kidney transplantation was performed at 9 years of age. In previous reports describing PAX2 mutations with FSGS, affected individuals with missense PAX2 mutations developed ESKD in adulthood, whereas one case with truncating PAX2 mutations developed ESKD in childhood similar to the current case. Our case highlighted the association of truncating PAX2 mutations with the risk of rapid progression to ESKD. Thus, PAX2 mutations should be included in genetic screening for such cases even in the absence of renal and urinary tract malformations.
Introduction
Renal coloboma syndrome (RCS, MIM#120330), also known as papillorenal syndrome, is an autosomal dominantly inherited disease associated with abnormal ocular and kidney findings attributable to the paired box protein 1 3 2 (PAX2) gene [1, 2] . Common renal findings seen in RCS are renal hypodysplasia (65%), vesicoureteral reflux (VUR) (14%), renal cysts (8%), multicystic dysplastic kidneys (6%), and other congenital anomalies of the kidney and urinary tract [2] . Phenotypic variability is reported in patients with RCS, ranging from typical RCS with congenital anomalies of the kidney and urinary tract (CAKUT) to focal segmental glomerulosclerosis (FSGS) without renal morphological abnormalities [2, 3] .
A few reports demonstrated that histological findings of patients with RCS were suggestive of FSGS [4] [5] [6] [7] and recent studies suggested that PAX2 mutations also cause familial FSGS [8, 9] . However, despite many reports of pathogenic variants in the PAX2 gene, a review of all reported cases to date does not reveal a consistent genotype-phenotype correlation and there have been no reports of a genotype-phenotype correlation including pathological findings [7] . Here we report a case of RCS with pathological findings of FSGS in which genetic analysis revealed a truncating PAX2 mutation. The patient rapidly progressed to end-stage kidney disease (ESKD). We also review previous literature on PAX2 mutation and/ or FSGS and speculate.
Case report
A 6-year-old boy, born to healthy parents, had a healthy brother and no remarkable family history. Coloboma of both his eyes was noted; his left eye had a functional ocellus but no vision. No history of urinary tract infections was noted and he showed normal neurological development. At 6 years of age, proteinuria was first identified in a school urinalysis screening along with chronic kidney disease. His urinary protein level was 0.5 g/day, and his serum creatinine (Cre) and cystatin C (CysC) levels were slightly elevated (0.75 mg/dL and 1.09 mg/L, estimate glomerular filtration rate [eGFR] 53.02 and 87.7 mL/min/1.73m 2 , respectively). The patient's height and weight were 114.3 cm (− 0.5 standard deviations [SD]) and 19.9 kg, respectively. Abdominal ultrasound showed normal-sized kidneys (right kidney, 6.5 × 3.0 cm [− 0.6 SD]; left kidney, 7.0 × 4.0 cm [− 0.3 SD]) and no signs of hydronephrosis. Voiding cystourethrography showed only grade 1 VUR. The kidney biopsy showed 21 acquisition glomeruli and most glomeruli showed a variety of sclerotic lesions (6 global, 8 segmental) with glomerular hyalinization ( Fig. 1a, b ). Tubular atrophy or expansion was present but no basal membrane findings suggestive of nephronophthisis were noted. Primitive duct or chondrification which was commonly observed in the dysplastic kidney was not seen. Thus, a pathological diagnosis was FSGS not otherwise specified (NOS by Columbia classification).
Genetic analysis revealed a novel insertion-deletion mutation (NM003987.4: c.70-72delinsA; Gly24Argfs*29) in exon 2 of the PAX2 gene, resulting in a truncated protein.
No mutation was found in WT1 or NPHS2. After a diagnosis of FSGS was confirmed, treatment with angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) was initiated. Thereafter, at 8 years of age, 2 weeks after a routine follow-up which showed Cre 2.09 mg/dL (eGFR 24.1) and CysC 3.0 (eGFR 26.90), he suddenly exhibited edema. The laboratory investigation revealed drastic worsening of kidney function (BUN 111.7, Cre 5.02 mg/dL [eGFR 11.7], CysC 4.42, [eGFR 15.75]). The second kidney biopsy showed ten acquisition glomeruli and six glomeruli showed global sclerosis (Fig. 1c) ; two glomeruli showed endocapillary proliferative glomerulonephritis and acute tubular damage with neutrophilic infiltration suspected to be post-infectious glomerulonephritis, superimposed on FSGS. (Fig. 1d, e ). Three months later, at 9 years of age, the patient underwent living donor kidney transplantation from his mother, and no recurrence of ESKD has been observed since then.
Discussion
The current case exhibited a typical ocular-renal phenotype consistent with a diagnosis of RCS with a truncating PAX2 mutation. Laboratory and imaging examinations findings were not suggestive of a CAKUT phenotype, while the kidney biopsy indicated FSGS. Reports of kidney biopsy findings of patients with RCS are relatively rare, probably because such patients are thought to be easy to diagnose based on kidney morphological evaluations prior to a kidney biopsy. We should, however, note that patients with PAX2 mutation can have FSGS with or without the ocular/CAKUT phenotype.
In the current case, a novel truncating PAX2 mutation (c.70-72delinsA:Gly24Argfs*29) was found in exon 2, which contains the paired box domain and comprising mutations most frequently seen in patients with RCS. According to the Leiden Open Variation Database (www. lovd.nl/PAX2) and the Human Gene Mutation Database (https ://www.hgmd.cf.ac.uk/ac/index ), approximately 100 pathogenic variants have been reported in the PAX2 gene so far. Truncating mutations were most frequently found in patients with typical RCS, whereas missense mutations were more frequently associated with the phenotype of familial FSGS [8] . Barua et al. speculated that PAX2 missense variants lead to an expanded phenotypic spectrum including FSGS owing to their haploinsufficiency and/or dominant-negative effects based on an in silico analysis and functional study [8] . Previously reported patients with biopsy proven FSGS with PAX2 mutations are listed in Table 1 . Patients with missense mutations of PAX2 showed clinical diagnosis of FSGS (Pedigree 1-7), whereas patients with truncating mutations exhibited classical RCS with coloboma findings (Pedigree 9-15). Our case with a frameshift mutation (pedigree 11) rapidly progressed to ESKD at 8 years of age. In addition, another case (pedigree 9) of truncating PAX2 mutation (c.69-70InsG: p.Val26Glyfs*28) progressed to ESKD at as early as 4 years old [9] . In contrast, familial FSGS patients with missense PAX2 mutations developed ESKD in adulthood (30-70 years old). Although we had to consider the possibility that ACEI/ARB use might worsen his kidney function in our case, we could say that affected individuals with truncating PAX2 mutations have a tendency of early progression to ESKD compared to those of with missense PAX2 mutations.
Currently, there are no formal criteria for the clinical diagnosis of RCS. Therefore, the disease entity and the correlation between RCS and PAX2 mutation are not thoroughly understood [10] . There is phenotypically heterogeneity and show a wide variation in the clinical presentation in affected individuals with PAX2 mutations [7] . Our case findings highlight the importance of urinalyses screening programs for children because non-symptomatic proteinuria was the only renal finding in this case. It is important to make an accurate diagnosis of RCS based on pathological findings coupled with genetic analysis. Accumulation of further cases and pathological analysis would help clarify the pathogenesis.
In conclusion, when encountering patients with FSGS of unknown etiology with or without ocular abnormalities, PAX2 mutations should be screened for even in the absence of evidence of renal malformation. 
